Latest Health Headlines: J&J's Settlement, Novartis' Legal Battle, and More

This health news summary covers various updates including Johnson & Johnson's settlement agreement, Novartis' legal setback, the FDA's approval of Ascendis Pharma's new therapy, Revance's private takeover deal, and Pfizer's RSV vaccine study results.

The health sector witnessed significant developments this week. Johnson & Johnson reached a pivotal point in its $6.5 billion talc settlement, gaining more than 75% approval from claimants alleging cancer links to its baby powder.

Meanwhile, Novartis faced a legal defeat as a Delaware court denied its request to block a generic version of its heart drug, Entresto, though the ruling is under appeal.

In other news, the FDA approved Ascendis Pharma's treatment for hypoparathyroidism, boosting the Danish company's shares, and Revance Therapeutics agreed to a $924 million acquisition deal with Crown Laboratories.

Lastly, Pfizer announced promising results from its RSV vaccine study, showing it generated strong immunity in adults with compromised immune systems.

(With inputs from agencies.)